Yan Leyfman Highlighted Science Study on In Vivo CAR-T Cell Generation for Cancer and Autoimmune Disease
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Breakthrough in CAR-T Delivery!
A new study by Hunter et al. introduces an in vivo strategy to generate CAR-T cells using CD8-targeted lipid nanoparticles (tLNPs) carrying anti-CD19 CAR mRNA — no ex vivo manufacturing required.
– Tumor control in preclinical models
– B cell depletion and immune reset in NHPs
– Potential for off-the-shelf, nonviral, scalable CAR-T therapy – in cancer and autoimmune diseaseThis could be a game-changer for accessibility and future clinical applications.”
Title: In vivo CAR T cell generation to treat cancer and autoimmune disease
Journal: Science
Authors: Theresa L. Hunter, Yanjie Bao, Yan Zhang, Daiki Matsuda, Romina Riener, Annabel Wang, John J. Li, Ferran Soldevila, David S. H. Chu, Duy P. Nguyen, Qian-Chen Yong, Brittany Ross, Michelle Nguyen, James Vestal, Scott Roberts, Diana Galvan, Jerel Boyd Vega, Donald Jhung, Matthew Butcher, Josephine Nguyen, Stanley Zhang, Claudia Fernandez, Jeffrey Chen, Carolina Herrera, Yi Kuo, E. Michael Pica, Goutam Mondal, Andrew L. Mammen, John Scholler, Steven P. Tanis, Stuart A. Sievers, Aric M. Frantz, Gregor B. Adams, Laura Shawver, Ramin Farzaneh-Far, Michael Rosenzweig, Priya P. Karmali, Adrian I. Bot, Carl H. June, Haig Aghajanian
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023